Treehouse Eyes and Johnson & Johnson Vision have partnered to give patients access to ACUVUE Abiliti Overnight Therapeutic Lenses for myopia management in collaboration with select practices in cities across the U.S., while also increasing myopia

AcuFocus announced that it has received an Approvable Letter from the FDA for its IC-8 small aperture IOL, which is designed for cataract patients.

The Global Myopia Awareness Coalition (GMAC), formed in early 2019, is composed of leading ophthalmic companies and eye health associations that agree on a clear need for greater public awareness about myopia in children.

Amydis announced the successful completion of a pre-IND (investigational new drug) meeting with the FDA regarding the development plans for a small-molecule tracer to detect TDP43 in the retina of amyotrophic lateral sclerosis (ALS) patients.

Cataracts affect most older adults at risk for dementia, and new research shows that cataract surgery is linked to a lower risk of dementia.

HyVIS, the European project coordinated by the IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology), is ready to begin.

In a three-month study, a bionic eye developed by a team of biomedical researchers from the University of Sydney and UNSW proved to be safe and stable for long-term implantation, paving the way for human trials.

Israeli company Ophthalmic Sciences has unveiled the IOPerfect, which the company describes as the world's first AI-based contactless IOP measuring device.

Omeros Corporation announced today that it has entered a definitive deal with Rayner Surgical Group Limited to sell OMIDRIA.

Nicox SA revealed positive post-hoc data from its Mississippi Phase 2b clinical trial, finding that once-daily dosed NCX 4251, fluticasone propionate ophthalmic suspension 0.1%, is beneficial in alleviating dry eye symptoms in a subgroup of patients.